Patents by Inventor Ae Nim Pae

Ae Nim Pae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210401782
    Abstract: The present invention relates to a pharmaceutical composition comprising (S)-2-(((4?-trifluoromethylbiphenyl-4-yl)methyl)amino)propanamide methanesulfonate or a pharmaceutically acceptable salt thereof as an effective ingredient for prevention or treatment of stroke.
    Type: Application
    Filed: April 1, 2019
    Publication date: December 30, 2021
    Applicant: NEUROBIOGEN CO.,LTD
    Inventors: Ki Duk PARK, Changjoon LEE, Soo-Jin OH, Ae Nim PAE, Sang Min LIM, Jong Hyun PARK, Min-Ho NAM, Hyoung Ihl KIM, Ji Young PARK, Jongwook CHO
  • Publication number: 20210317083
    Abstract: The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.
    Type: Application
    Filed: August 19, 2019
    Publication date: October 14, 2021
    Inventors: Ki Duk PARK, Ae Nim PAE, Sang Min LIM, Jong Hyun PARK, Ji Won CHOI, Siwon KIM, Hyeon Jeong KIM, Seul Ki YEON
  • Patent number: 11053190
    Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: July 6, 2021
    Assignee: NeuroBiogen Co., Ltd.
    Inventors: Ki Duk Park, ChangJoon Justin Lee, Dong Jin Kim, Ae Nim Pae, Hyun Ah Choo, Sun Joon Min, Yong Koo Kang, Yun Kyung Kim, Hyo Jung Song, Ji Won Choi, Min Ho Nam, Jun Young Heo, Seul Ki Yeon, Bo Ko Jang, Eun Ji Ju, Seon Mi Jo, Jong-Hyun Park
  • Publication number: 20210030700
    Abstract: The present invention relates to a pharmaceutical composition comprising (S)-2-(((4?-trifluoromethylbiphenyl-4-yl)methyl)amino)propanamide methanesulfonate or a pharmaceutically acceptable salt thereof as an effective ingredient for prevention or treatment of spinal cord injury.
    Type: Application
    Filed: February 7, 2019
    Publication date: February 4, 2021
    Applicant: NEUROBIOGEN CO.,LTD
    Inventors: Ki Duk PARK, Changjoon LEE, Ae Nim PAE, Soo-Jin OH, Sang Min LIM, Jong Hyun PARK, Jungmoo LEE, Yoon HA, Hye Yeong LEE
  • Publication number: 20200308104
    Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 1, 2020
    Inventors: Ki Duk PARK, ChangJoon Justin LEE, Dong Jin KIM, Ae Nim PAE, Hyun Ah CHOO, Sun Joon MIN, Yong Koo KANG, Yun Kyung KIM, Hyo Jung SONG, Ji Won CHOI, Min Ho NAM, Jun Young HEO, Seul Ki YEON, Bo Ko JANG, Eun Ji JU, Seon Mi JO, Jong-Hyun PARK
  • Publication number: 20200199065
    Abstract: The present invention relates to novel functional derivatives of alanine and proline amino acids. The compounds of the present invention were confirmed to have a very superior antifungal or fungicidal effect. In addition, the compounds of the present invention were confirmed to exhibit a synergistic effect when co-administered with an existing antifungal preparation. Moreover, the compounds of the present invention showed activity on a wide range of fungi. Therefore, the compounds of the present invention can be widely used in a field which requires the treatment with an antifungal or fungicidal preparation against human infectious fungi, animal infectious fungi, and phytopathogenic fungi.
    Type: Application
    Filed: October 30, 2017
    Publication date: June 25, 2020
    Inventors: Ki Duk Park, Yong-Sun Bahn, Jong-Seung Lee, Kyung-Tae Lee, Ae Nim Pae, Seul Ki Yeon, Yong Koo Kang, Jong Hyun Park, Siwon Kim, Bo Ko Jang, Ji Won Choi
  • Patent number: 10676425
    Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: June 9, 2020
    Assignee: MEGABIOWOOD CO., LTD
    Inventors: Ki Duk Park, ChangJoon Justin Lee, Dong Jin Kim, Ae Nim Pae, Hyun Ah Choo, Sun Joon Min, Yong Koo Kang, Yun Kyung Kim, Hyo Jung Song, Ji Won Choi, Min Ho Nam, Jun Young Heo, Seul Ki Yeon, Bo Ko Jang, Eun Ji Ju, Seon Mi Jo, Jong-Hyun Park
  • Patent number: 10544427
    Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: January 28, 2020
    Assignee: Korea Institute of Science and Technology
    Inventors: Do Hee Kim, Seul Gi Shin, Sung Su Lim, Ae Nim Pae, Dong Jin Kim, Yun Kyung Kim
  • Patent number: 10421779
    Abstract: The present invention relates to a carbazole compound having anti-virus activity, and more particularly, to a novel compound selected from the group of consisting of a carbazole compound which shows excellent anti-proliferative efficacy against hepatitis C virus (HCV), a pharmaceutically acceptable salt thereof, a hydrate thereof, and an isomer thereof; an anti-virus pharmaceutical composition including the novel compound as an active ingredient; a pharmaceutical composition for preventing or treating liver diseases caused by hepatitis C virus; and a method of preparing the novel compound.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: September 24, 2019
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Gyo Chang Keum, Eunice Eun Kyeong Kim, Sung Key Jang, Hee Sun Kim, Ae Nim Pae, Hua Li, Jin Hyeong Park, Jin Sook Kwak
  • Patent number: 9962384
    Abstract: Disclosed is a levosimendan compound, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, which is used for the prevention and/or treatment of diseases caused by tau aggregation or phosphorylation, such as neurodegenerative diseases (e.g., Alzheimer disease). In accordance with yet another aspect of the present invention, there is provided a health functional food for preventing or treating tau aggregation-related diseases, containing a levosimendan compound or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 8, 2018
    Assignee: Korea Institute of Science and Technology
    Inventors: Yun Kyung Kim, Sung Su Lim, Do Hee Kim, Md. Mamunul Haque, Seul Gi Shin, Ha Eun Lee, Tae Hun Kim, Sang Min Lim, Ae Nim Pae
  • Publication number: 20180119169
    Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.
    Type: Application
    Filed: September 20, 2017
    Publication date: May 3, 2018
    Applicant: Korea Institute of Science and Technology
    Inventors: Do Hee KIM, Seul Gi Shin, Sung Su Lim, Ae Nim Pae, Dong Jin Kim, Yun Kyung Kim
  • Publication number: 20180057527
    Abstract: The present invention relates to a carbazole compound having anti-virus activity, and more particularly, to a novel compound selected from the group of consisting of a carbazole compound which shows excellent anti-proliferative efficacy against hepatitis C virus (HCV), a pharmaceutically acceptable salt thereof, a hydrate thereof, and an isomer thereof; an anti-virus pharmaceutical composition including the novel compound as an active ingredient; a pharmaceutical composition for preventing or treating liver diseases caused by hepatitis C virus; and a method of preparing the novel compound.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Applicants: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Gyo Chang KEUM, Eunice Eun Kyeong KIM, Sung Key JANG, Hee Sun KIM, Ae Nim PAE, Hua LI, Jin Hyeong PARK, Jin Sook KWAK
  • Publication number: 20170298011
    Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 19, 2017
    Inventors: Ki Duk PARK, ChangJoon Justin LEE, Dong Jin KIM, Ae Nim PAE, Hyun Ah CHOO, Sun Joon MIN, Yong Koo KANG, Yun Kyung KIM, Hyo Jung SONG, Ji Won CHOI, Min Ho NAM, Jun Young HEO, Seul Ki YEON, Bo Ko JANG, Eun Ji JU, Seon Mi JO, Jong-Hyun PARK
  • Patent number: 9493423
    Abstract: Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 15, 2016
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ghil Soo Nam, Kyung Il Choi, Jung Hyun Kim, Ae Nim Pae, Jin Ri Hong, Jae Kyun Lee
  • Publication number: 20150329533
    Abstract: Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.
    Type: Application
    Filed: February 26, 2015
    Publication date: November 19, 2015
    Inventors: Ghil Soo NAM, Kyung Il CHOI, Jung Hyun KIM, Ae Nim PAE, Jin Ri HONG, Jae Kyun LEE
  • Patent number: 9012481
    Abstract: Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: April 21, 2015
    Assignee: Korea Institute of Science and Technology
    Inventors: Hoh-Gyu Hahn, Kee-Dal Nam, Dong-Yun Shin, Chan-Ho Park, Sung-Woo Cho, Eun-A Kim, Ghil-Soo Nam, Kyung-Il Chol, Seon-Hee Seo, Hee-Sup Shin, Dong-Jin Kim, Ae-Nim Pae, Hye-Jin Chung, Hyun-Ah Choo, Hye-Whon Rhim, Yong-Seo Cho, Eun-Joo Roh, Gyo-Chang Keum, Kee-Hyun Choi, Kye-Jung Shin, Chan-Seong Cheong, Jae-Kyun Lee, Yong-Koo Kang, Young-Soo Kim, Woong-Seo Park, Key-Sun Kim, He-Sson Chung, Chi-Man Song, Sun-Joon Min, Eunice Eun-Kyeong Kim, Cheol-Ju Lee, Soon-Bang Kang
  • Patent number: 8993766
    Abstract: The present invention relates to a method for preparing tetrabenazine (TBZ) and dihydrotetrabenazine (DTBZ), and more specifically to a method for preparing tetrabenazine (TBZ) and dihydrotetrabenazine (DTBZ) by using simple and short reaction processes of using 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline and 4-methyl-2-(3-(trimethylsilyl)prop-1-ene-2-yl)pentane as starting materials to sequentially perform an alkylation reaction, an Aza-Prins cyclization reaction in the presence of an oxidant and an oxidation reaction.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 31, 2015
    Assignee: Korea Institute of Science and Technology
    Inventors: Sun Joon Min, Yong Seo Cho, Jae Kyun Lee, Ae Nim Pae, Young Wook Son
  • Patent number: 8946431
    Abstract: Provided is a 2-(substituted ethynyl)quinoline derivative having an mGluR5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mGluR5 receptor-mediated diseases such as Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: February 3, 2015
    Assignee: Korea Institute of Science and Technology
    Inventors: Sun Joon Min, Yong Seo Cho, Ae Nim Pae, Eun Jeong Lim, Ji Yeong Kim, Myung Hee Son, Jae Kyun Lee
  • Patent number: 8895558
    Abstract: The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: November 25, 2014
    Assignee: Green Cross Corporation
    Inventors: Jinhwa Lee, Suk Youn Kang, Eun-Jung Park, Kwang-Seop Song, Min Ju Kim, Hee Jeong Seo, Suk Ho Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
  • Patent number: 8895602
    Abstract: The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: November 25, 2014
    Assignee: Korea Institute of Science and Technology
    Inventors: Ghil Soo Nam, Kyung Il Choi, Ae Nim Pae, Seon Hee Seo, Hyun Ah Choo, Gyo Chang Keum, Jung Hyun Kim